FENNEC PHARMACEUTICALS INC. (FENC)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 9,652 | 8,751 | 6,974 | 7,262 |
| Selling and marketing | 4,354 | 2,947 | 4,601 | 4,672 |
| Research and development | 107 | 94 | 97 | 157 |
| General and administrative | 6,956 | 6,145 | 6,121 | 6,864 |
| Cost of product sales | 967 | 373 | 1,357 | 608 |
| Total operating expenses | 12,384 | 9,559 | 12,176 | 12,301 |
| (loss)/income from operations | -2,732 | -808 | -5,202 | -5,039 |
| Interest income (expense), operating | - | - | - | 570 |
| Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs | - | - | - | 1,044 |
| Debt securities, available-for-sale, unrealized loss | - | - | 3 | - |
| Interest income | 171 | 236 | 516 | - |
| Interest expense | 594 | 592 | 1,025 | - |
| Unrealized foreign exchange (loss)/gain | 17 | 13 | - | -17 |
| Amortization expense | 13 | 13 | 21 | 23 |
| Unrealized loss on securities | 1 | 1 | - | - |
| Total other expense | -420 | -357 | -533 | -514 |
| Net (loss)/income | -3,152 | -1,165 | -5,735 | -5,553 |
| Earnings per share, basic | -0.11 | -0.04 | -0.21 | -0.2 |
| Earnings per share, diluted | -0.11 | -0.04 | -0.21 | -0.2 |
| Weighted average number of shares outstanding, basic | 27,664,000 | 27,578,000 | 27,371,000 | 27,297,000 |
| Weighted average number of shares outstanding, diluted | 27,664,000 | 27,578,000 | 27,371,000 | 27,297,000 |